Výsledky vyhledávání - "Kris Awerkamp"

Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer

Autor: K. Alex Hodge, Maysa M. Abu-Khalaf, Frances Valdes, Rita Murphy, William M. Sikov, Neelima Denduluri, Bryant Dunetz, Christos Hatzis, Mariaelena Pierobon, Kris Awerkamp, Emanuel F. Petricoin, Daniel Zelterman, Monica M. Mita

Publikováno v: Cancer Research. 81:PS5-28

Background: Three CDK 4/6 inhibitors (inh) are FDA approved in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC), however, there are no validated predictive markers of response to this class of drugs. Approximately

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb9de3683c25a62f33d071dfb77ace28
https://doi.org/10.1158/1538-7445.sabcs20-ps5-28

Zobrazit plný text záznamu

Abstract CT153: SDX-7320 elicits improvements in tumor-related and metabolic biomarkers: Results of a phase 1 dose-escalation study in patients with advanced refractory or late-stage solid tumors

Autor: Benjamin Mayes, Alfred Anderson-Villaluz, Alain C. Mita, Kimberly Sullivan, Jasgit C. Sachdev, Neal Salomon, James Shanahan, David Browning, Bradley Carver, Petersen John S, Kris Awerkamp, Johanna C. Bendell, Joe Johnson, Peter Cornelius, Michael S. Gordon, David J. Turnquist, Monica M. Mita

Publikováno v: Cancer Research. 80:CT153-CT153

Background and Rationale: Metabo-oncology is the study of specific tumor types whose growth and/or metastasis is accelerated by metabolic dysfunction, often associated with hyper-adiposity. In this setting the metabolic hormones leptin, adiponectin a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a1e8e2d1da2955570d3dc52fc54412c
https://doi.org/10.1158/1538-7445.am2020-ct153

Zobrazit plný text záznamu

Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3)

Autor: Mariaelena Pierobon, Daniel Zelterman, S Christensen, Maysa M. Abu-Khalaf, Andres Forero-Torres, Bryant Dunetz, Christos Hatzis, Rachel L. Yung, Rita Murphy, Amy S. Clark, Monica M. Mita, Neelima Denduluri, Lance A. Liotta, Kris Awerkamp, E. Petricoin, F Valdes-Albini

Publikováno v: Cancer Research. 79:OT3-02

Background: Palbociclib, ribociclib and abemaciclib are 3 cyclin-dependent kinase (CDK) 4/6 inhibitors (inh) approved by the FDA for treatment of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (MBC). We hypothesize tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21b8641bf20315d3e3210e645dffc2b4
https://doi.org/10.1158/1538-7445.sabcs18-ot3-02-06

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání